Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX6 Induction for Locally Advanced Esophageal Cancer
NCT03110926Phase 2Active, not recruiting
- Sponsor
- University of Rochester
- Start
- Jun 2017
- Primary completion
- May 2027
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and folinic acid in esophageal cancer, sponsored by University of Rochester. Primary endpoint: Disease-free survival rate at 2 years. Started Jun 2017; status: active, not recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03110926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110926.